David L. Swerdlow

29.6k total citations · 9 hit papers
188 papers, 16.0k citations indexed

About

David L. Swerdlow is a scholar working on Infectious Diseases, Epidemiology and Modeling and Simulation. According to data from OpenAlex, David L. Swerdlow has authored 188 papers receiving a total of 16.0k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Infectious Diseases, 60 papers in Epidemiology and 41 papers in Modeling and Simulation. Recurrent topics in David L. Swerdlow's work include COVID-19 epidemiological studies (41 papers), Viral gastroenteritis research and epidemiology (36 papers) and Influenza Virus Research Studies (35 papers). David L. Swerdlow is often cited by papers focused on COVID-19 epidemiological studies (41 papers), Viral gastroenteritis research and epidemiology (36 papers) and Influenza Virus Research Studies (35 papers). David L. Swerdlow collaborates with scholars based in United States, United Kingdom and Mongolia. David L. Swerdlow's co-authors include Lyn Finelli, Sean F. Altekruse, Marc Lipsitch, Patricia I. Fields, P.H. Sparling, Patricia M. Griffin, Frederick J. Angulo, Patricia M. Griffin, Josefa M. Rangel and Norman J. Stern and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

David L. Swerdlow

186 papers receiving 15.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Botulinum Toxin as a Biological Weapon

2001 1.3k citations Robert Schechter, Thomas V. Inglesby et al. JAMA profile →
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

2021 1.0k citations Frederick J. Angulo, John M. McLaughlin et al. profile →
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.

1999 1.0k citations David L. Swerdlow et al. profile →
Epidemiology ofEscherichia coliO157:H7 Outbreaks, United States, 1982–2002

2005 946 citations P.H. Sparling, David L. Swerdlow et al. Emerging infectious diseases profile →
Defining the Epidemiology of Covid-19 — Studies Needed

2020 779 citations Marc Lipsitch, David L. Swerdlow et al. profile →
Campylobacter jejuni—An Emerging Foodborne Pathogen

1999 642 citations Sean F. Altekruse, David L. Swerdlow et al. Emerging infectious diseases profile →
Epidemiology of Seafood-Associated Infections in the United States

2010 418 citations David L. Swerdlow et al. profile →
2014 MERS-CoV Outbreak in Jeddah — A Link to Health Care Facilities

2015 337 citations David L. Swerdlow et al. profile →
Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis

2022 116 citations John M. McLaughlin, David L. Swerdlow et al. Open Forum Infectious Diseases profile →

Peers

Countries citing papers authored by David L. Swerdlow

Since Specialization

Citations

This map shows the geographic impact of David L. Swerdlow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L. Swerdlow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L. Swerdlow more than expected).

Fields of papers citing papers by David L. Swerdlow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David L. Swerdlow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L. Swerdlow. The network helps show where David L. Swerdlow may publish in the future.

Co-authorship network of co-authors of David L. Swerdlow

This figure shows the co-authorship network connecting the top 25 collaborators of David L. Swerdlow. A scholar is included among the top collaborators of David L. Swerdlow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David L. Swerdlow. David L. Swerdlow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Global epidemiology of serogroup Y invasive meningococcal disease: a literature review 2024 ·Epidemiology and Infection ·Myint Tin Tin Htar, Jamie Findlow, Paul Balmer, David L. Swerdlow	2
2	Estimating the Burden of Clinically Significant Staphylococcus aureus Infections and Predictors for Hospitalization for Skin and Soft Tissue Infections, Fulton County, Georgia, 2017 2023 ·Open Forum Infectious Diseases ·(unknown), (unknown), Susan M. Ray, Amber Britton, David L. Swerdlow, Scott K. Fridkin	0
3	The Role of Children in the Transmission of SARS-CoV-2, a Shifting Paradigm 2023 ·Infectious Diseases in Clinical Practice ·Adriano Arguedas, David L. Swerdlow, Daniel Curcio	0
4	Estimates of Presumed Population Immunity to SARS-CoV-2 by State in the United States, August 2021 2022 ·Open Forum Infectious Diseases ·Marie C. D. Stoner, Frederick J. Angulo, Sarah Rhea, Línda Morris Brown, Jessica E. Atwell, Jennifer L. Nguyen, John M. McLaughlin, David L. Swerdlow, Pia D. M. MacDonald	5
5	Leveraging Serosurveillance and Postmortem Surveillance to Quantify the Impact of Coronavirus Disease 2019 in Africa 2022 ·Clinical Infectious Diseases ·(unknown), (unknown), David L. Swerdlow, Cécile Viboud, Muhammed Semakula, Marc Lipsitch, Mauricio Santillana	4
6	Risk factors for non-invasive (skin and soft tissue) and invasive Staphylococcus aureus infections among children and adults living in southeastern USA: a retrospective cohort study 2022 ·BMJ Open ·(unknown), Traci Leong, Andrew R. Webster, (unknown), Scott K. Fridkin, Susan M. Ray, David L. Swerdlow, Lilly Cheng Immergluck	6
7	Infectious Disease Modeling Methods as Tools for Informing Response to Novel Influenza Viruses of Unknown Pandemic Potential 2015 ·Clinical Infectious Diseases ·Manoj Gambhir, Catherine H. Bozio, Justin J. O’Hagan, Amra Uzicanin, (unknown), Matthew Biggerstaff, David L. Swerdlow	8
8	Economic evaluation of typhoid vaccination in a prolonged typhoid outbreak setting: The case of Kasese district in Uganda 2015 ·Vaccine ·Cristina Carias, Maroya Spalding Walters, (unknown), Kashmira Date, David L. Swerdlow, Maya Vijayaraghavan, Eric Mintz	11
9	2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations in the United States at the Start of the First Pandemic of the 21st Century 2010 ·Clinical Infectious Diseases ·David L. Swerdlow, Lyn Finelli, Carolyn B. Bridges	30
10	Update: influenza activity - United States, April-August 2009. 2009 ·MMWR Morbidity and Mortality Weekly Report ·L. Finelli, (unknown), Lenee Blanton, Scott Epperson, Rosaline Dhara, Ashley Fowlkes, Desiree Mustaquim, Laurie Kamimoto, Krista Kniss, A. Klimov, Larisa V. Gubareva, Alicia M. Fry, Anthony E. Fiore, Daniel B. Jernigan, J. Bresee, David L. Swerdlow	39
11	Invasive Salmonella Infections in the United States, 1996-2006 2008 ·46th Annual Meeting ·David L. Swerdlow	1
12	Human Monocytic Ehrlichiosis and Human Granulocytic Anaplasmosis in the United States, 2001–2002 2006 ·Annals of the New York Academy of Sciences ·Linda J. Demma, Robert C. Holman, Jennifer H. McQuiston, J W Krebs, David L. Swerdlow	12
13	Rocky Mountain Spotted Fever in the United States, 1997–2002 2006 ·Vector-Borne and Zoonotic Diseases ·Alice S. Chapman, Staci M. Murphy, Linda J. Demma, Robert C. Holman, Aaron T. Curns, Jennifer H. McQuiston, John W. Krebs, David L. Swerdlow	70
14	Serologic Evidence for Exposure to Rickettsia rickettsii in Eastern Arizona and Recent Emergence of Rocky Mountain Spotted Fever in This Region 2006 ·Vector-Borne and Zoonotic Diseases ·Linda J. Demma, Marc Traeger, Dianna M. Blau, (unknown), Brian J. Johnson, (unknown), (unknown), (unknown), Craig Levy, William L. Nicholson, C.J. Duncan, Karen E. Heath, James E. Cheek, David L. Swerdlow, Jennifer H. McQuiston	46
15	SalmonellaEnteritidis Infections, United States, 1985–1999 2004 ·Emerging infectious diseases ·Mary Patrick, Penny M. Adcock, Thomas M. Gomez, Sean F. Altekruse, (unknown), Robert V. Tauxe, David L. Swerdlow	225
16	Botulinum toxin as a biological weapon 2001 ·JAMA ·Stephen S. Arnon, Robert Schechter, Thomas V. Inglesby, Donald A. Henderson, John G. Bartlett, Michael S. Ascher, Edward M. Eitzen, Anne D. Fine, Jerome Hauer, Marcelle Layton, Scott R. Lillibridge, Michael T. Osterholm, Tara O’Toole, Gerald Parker, Trish M. Perl, Philip K. Russell, David L. Swerdlow, Kevin Tonat	95
17	An Outbreak ofCampylobacter jejuniInfections Associated with Food Handler Contamination: The Use of Pulsed‐Field Gel Electrophoresis 2001 ·The Journal of Infectious Diseases ·Sonja J. Olsen, Gail R. Hansen, Linda Bartlett, Collette Fitzgerald, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), David L. Swerdlow	48
18	Biological and chemical terrorism: strategic plan for preparedness and response. 2000 ·MMWR Morbidity and Mortality Weekly Report ·Samuel L. Groseclose, (unknown), Elaine W. Gunter, (unknown), (unknown), David A. Ashford, Robert B. Craven, Robert P. Gaynes, Stephen Morse, C. J. Peters, (unknown), David L. Swerdlow, Scott Deitchman, Paul K. Halverson, (unknown), Patricia Quinlisk	238
19	FOODBORNE DISEASES 1998 ·Infectious Disease Clinics of North America ·Laurence Slutsker, Sean F. Altekruse, David L. Swerdlow	97
20	Epidemiology and control of egg-associated Salmonella enteriditis in the United States of America 1997 ·Revue Scientifique et Technique de l OIE ·(unknown), Patricia L. White, Jean Guard, W. Schlosser, Richard K. Gast, Eric D. Ebel, Jeffrey A. Farrar, Thomas M. Gomez, Joseph M. Madden, (unknown), Ann McNamara, Roberta A. Morales, (unknown), P.H. Sparling, (unknown), David L. Swerdlow	124

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact